Association of plasma ceramides with short-term and lifetime risk of MACE in coronary atherosclerotic heart disease patients: a prospective cohort study
BMJ Open · 2025
DOI: 10.1136/bmjopen-2024-094100 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift BMJ Open, 2025. Verfasst von Xiaolu Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Research Center, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital Affiliated to Capital Medical Unive…. Hauptthemen laut MEDLINE: Coronary Artery Disease, Ceramides. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objectives
To develop a CERT SCORE utilising both odd-chain and even-chain ceramide species, and to evaluate its association with short-term and lifetime cardiovascular risk in patients with coronary atherosclerotic heart disease (CAD).
Design
Prospective cohort study.
Setting
A patients-based cohort in the Beijing Anzhen Hospital, Capital Medical University.
Participants
CAD patients were defined as having at least one coronary artery stenosis of ≥50% as assessed by coronary angiography or CT angiography. Main outcomes and measures Major adverse cardiac events (MACE) including all-cause death, myocardial infarction, heart failure, cerebral infarction and readmission.
Results
We quantified 13 ceramide species and calculated the ratios of Cer(d18:1/14:0) and Cer(d18:1/24:0). Based on these measurements, Cer(d18:1/19:0), Cer(d18:1/19:0)/Cer(d18:1/14:0), Cer(d18:1/19:0)/Cer(d18:1/24:0) and Cer(d18:1/21:0)/Cer(d18:1/24:0) were selected to construct the CERT SCORE. Using this score, patients were classified into two distinct risk categories for MACE: low-risk (score 0–6) and high-risk (score 7–12). The high-risk group exhibited a significantly higher short-term risk of MACE (HR 2.10; 95% CI 1.50 to 2.94) compared with the low-risk group. The cumulative MACE risk in the low- and high-risk groups during the 1000-day follow-up was 25.45% and 44%, respectively. Subgroup analyses revealed that the presence of multivessel coronary artery lesions did not significantly modify the association between the CERT SCORE and short-term MACE risk (p value for interaction=0.967). Furthermore, in the age groups of 41–50 years, 51–60 years and 61–70 years, lifetime risk was significantly elevated in the high-risk group compared with the low-risk group.
Conclusion
We have developed a ceramide-based risk stratification tool (CERT SCORE) that demonstrates robust predictive value for identifying high-risk MACE patients among CAD patients. This tool offers considerable clinical utility for guiding patient management and informing therapeutic decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Research Center, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China.
- The Science and Technology Service Office, Jinan Vocational College, Jinan, Shandong, China.
- Experimental Research Center, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China jhf@pku.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, X., Zhang, R., Chen, X., Bao, S., & Jiang, H. (2025). Association of plasma ceramides with short-term and lifetime risk of MACE in coronary atherosclerotic heart disease patients: a prospective cohort study. BMJ Open. https://doi.org/10.1136/bmjopen-2024-094100
Vancouver
Li X, Zhang R, Chen X, Bao S, Jiang H. Association of plasma ceramides with short-term and lifetime risk of MACE in coronary atherosclerotic heart disease patients: a prospective cohort study. BMJ Open. 2025. doi:10.1136/bmjopen-2024-094100
BibTeX
@article{Li2025,
author = {Li, Xiaolu and Zhang, Rui and Chen, Xu and Bao, Suya and Jiang, Hongfeng},
title = {Association of plasma ceramides with short-term and lifetime risk of MACE in coronary atherosclerotic heart disease patients: a prospective cohort study},
journal = {BMJ Open},
year = {2025},
doi = {10.1136/bmjopen-2024-094100}
}
EUVIMED